NCT06948786View on ClinicalTrials.gov

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 14, 2025

Primary Completion Date

July 31, 2031

Study Completion Date

July 31, 2031

Conditions
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaRecurrent Follicular LymphomaRefractory Follicular Lymphoma
Interventions
DRUG

Pirtobrutinib

Given PO

BIOLOGICAL

Mosunetuzumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample and oral swab and/or rectal swab collection

PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Computed Tomography

Undergo CT and PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Washington

OTHER